Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE005 (FRA) (Dr. Muller)
· consented 2022-06-16
Adverse events
4
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-07-30 (study day 34); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-01-23 (study day 211); relationship: Y
moderate
assessed
2026-08-18
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-08-27 (study day 427); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-30 (study day 522); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.